It was established that about 30% of the administered dose of tetramezine was bound to plasma proteins in healthy donors. This should not significantly influence the strength of its pharmacological action in the absence of binding to blood cellular components.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. Begg, Clinical Pharmacology [in Russian], BINOM, Moscow (2004), p. 20.
A. A. Prokopov, L. I. Kotlova, and A. S. Berlyand, Khim.-farm. Zh., 40(9), 3 – 4 (2006); Pharm. Chem. J., 40(9), 463 – 464 (2006).
A. A. Prokopov, L. I. Kotlova, and A. S. Berlyand, Khim.-farm. Zh., 41(1), 8 – 9 (2007); Pharm. Chem. J., 41(1), 7 – 9 (2007).
D. G. Shand, D. W. Kornhauser, and G. R. Wilkinson, J. Pharm. Exp. Ther., V, 424 – 432 (1975).
A. A. Prokopov, L. I. Kotlova, and A. S. Berlyand, Khim.-farm. Zh., 39(7), 8 – 12 (2005); Pharm. Chem. J., 39(7), 8 – 12 (2005).
Author information
Authors and Affiliations
Additional information
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 49, No. 6, pp. 55 – 56, June, 2015.
Rights and permissions
About this article
Cite this article
Belyak, L.I., Berlyand, A.S. & Prokopov, A.A. Investigation of Tetramezine Binding to Plasma Proteins in Healthy Donors. Pharm Chem J 49, 417–418 (2015). https://doi.org/10.1007/s11094-015-1297-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-015-1297-6